domingo, 13 de noviembre de 2016

Technological considerations for genome-guided diagnosis and management of cancer. - PubMed - NCBI

Technological considerations for genome-guided diagnosis and management of cancer. - PubMed - NCBI
 2016 Oct 26;8(1):112.

Technological considerations for genome-guided diagnosis and management of cancer.

Abstract

Technological, methodological, and analytical advances continue to improve the resolution of our view into the cancer genome, even as we discover ways to carry out analyses at greater distances from the primary tumor sites. These advances are finally making the integration of cancer genomic profiling into clinical practice feasible. Formalin fixation and paraffin embedding, which has long been the default pathological biopsy medium, is now being supplemented with liquid biopsy as a means to profile the cancer genomes of patients. At each stage of the genomic data generation process-sample collection, preservation, storage, extraction, library construction, sequencing, and variant calling-there are variables that impact the sensitivity and specificity of the analytical result and the clinical utility of the test. These variables include sample degradation, low yields of nucleic acid, and low variant allele fractions (proportions of assayed molecules carrying variant allele(s)). We review here the most common pre-analytical and analytical factors relating to routine cancer patient genome profiling, some solutions to common challenges, and the major sample preparation and sequencing technology choices available today.
PMID:
 
27784341
 
PMCID:
 
PMC5080740
 
DOI:
 
10.1186/s13073-016-0370-4
[PubMed - in process] 
Free PMC Article

No hay comentarios:

Publicar un comentario en la entrada